Jasper Therapeutics(US:JSPR) Newsfileยท2025-11-06 01:57Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the November 18, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without upfront costs through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by November 18, 2025, to serve as lead plaintiff, representing other class members in the litigation [3][6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant settlements for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving over $438 million in recoveries for investors in 2019 alone [4]. Group 3: Allegations Against Jasper Therapeutics - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact the clinical and commercial prospects of its products, particularly briquilimab [5]. - The failure to disclose these issues allegedly led to inflated business and financial prospects, resulting in investor damages when the true information became public [5].